Your browser is no longer supported. Please, upgrade your browser.
ACT [NYSE]
Actavis plc
IndexS&P 500 P/E- EPS (ttm)-6.09 Insider Own0.20% Shs Outstand405.00M Perf Week-4.16%
Market Cap122.03B Forward P/E14.23 EPS next Y21.17 Insider Trans0.00% Shs Float389.04M Perf Month3.76%
Income-1630.50M PEG- EPS next Q4.07 Inst Own65.10% Short Float6.43% Perf Quarter17.76%
Sales13.06B P/S9.34 EPS this Y-40.80% Inst Trans8.06% Short Ratio7.86 Perf Half Y21.50%
Book/sh106.67 P/B2.82 EPS next Y20.37% ROA-4.00% Target Price337.50 Perf Year48.48%
Cash/sh0.62 P/C486.19 EPS next 5Y20.00% ROE-8.00% 52W Range184.71 - 317.72 Perf YTD17.06%
Dividend- P/FCF62.00 EPS past 5Y-42.20% ROI-2.70% 52W High-5.16% Beta0.30
Dividend %- Quick Ratio1.00 Sales past 5Y36.10% Gross Margin51.70% 52W Low63.13% ATR6.32
Employees21600 Current Ratio1.40 Sales Q/Q46.00% Oper. Margin-7.20% RSI (14)52.19 Volatility2.12% 1.91%
OptionableYes Debt/Eq0.55 EPS Q/Q-224.70% Profit Margin-11.70% Rel Volume1.03 Prev Close300.63
ShortableYes LT Debt/Eq0.52 EarningsApr 30 BMO Payout- Avg Volume3.19M Price301.32
Recom1.70 SMA200.26% SMA505.08% SMA20021.13% Volume3,274,209 Change0.23%
Mar-03-15Reiterated Deutsche Bank Buy $330 → $336
Feb-20-15Reiterated Argus Buy $310 → $340
Feb-19-15Reiterated RBC Capital Mkts Top Pick $325 → $330
Feb-19-15Reiterated Canaccord Genuity Buy $300 → $352
Jan-21-15Reiterated Deutsche Bank Buy $280 → $330
Jan-13-15Reiterated CRT Capital Buy $270 → $288
Nov-21-14Reiterated Argus Buy $285 → $310
Nov-20-14Reiterated RBC Capital Mkts Top Pick $291 → $323
Nov-18-14Reiterated UBS Buy $278 → $333
Nov-06-14Reiterated RBC Capital Mkts Top Pick $286 → $291
Sep-22-14Downgrade Barclays Overweight → Equal Weight $250 → $250
Aug-06-14Reiterated UBS Buy $237 → $254
Jul-02-14Reiterated CRT Capital Buy $245 → $275
Jun-27-14Initiated Canaccord Genuity Buy $275
May-12-14Upgrade RBC Capital Mkts Outperform → Top Pick $252 → $259
May-01-14Reiterated CRT Capital Buy $230 → $245
Apr-28-14Reiterated National Alliance Securities Buy $246 → $259
Apr-17-14Initiated National Alliance Securities Buy $246
Feb-21-14Reiterated RBC Capital Mkts Outperform $240 → $249
Feb-19-14Reiterated UBS Buy $202 → $237
Mar-26-15 05:32PM  How Billionaire Leon Coopermans Top Holdings Performed Amid Subpoena News at Insider Monkey
02:02PM  A look at Leon Cooperman, subject of SEC inquiry at CNBC
01:06PM  EMD Finances Yankee Corporate Issue Is the Largest in 2015
12:53PM  Kraft Foods And The Rise Of Wall Street's Buy And Hold Kingpins at Forbes
12:50PM  Highlights of Blue Ridge Capitals 4Q14 Holdings
10:06AM  Farallon Capital Adds a New Position in CareFusion Corporation
09:35AM  With New Valeant Pharmaceuticals Intl Inc (VRX) Stake, Bill Ackman Maintains Large Exposure to Healthcare Sector at Insider Monkey
Mar-25-15 03:06PM  Is a Para IV Filing Rewarding for a Generic Company?
02:06PM  Regulations Are Instrumental in the Marketing Authorization Process
01:05PM  Why Is the Generics Industry Controlled by Regulations?
12:07PM  Bargaining Power Is in the Hands of the Distribution Industry
11:10AM  4 Top-Ranked Health Care ETFs for a Healthy Portfolio - ETF News And Commentary
09:30AM  Zacks Rank #1 Additions for Wednesday - Tale of the Tape
Mar-24-15 10:50AM  Talking Allergan at Tulane: a 'Horse Choker,' the 'Shamarendum' and More at The Wall Street Journal
10:29AM  Will pharma rally continue?
Mar-23-15 01:05PM  Generics Are Climbing up the Value Chain
11:05AM  The Federal Reserve: Patient No More?
09:05AM  What Two Factors Are Driving the US Generics Market?
08:21AM  5 Rocket Stocks That Are Ready for Blastoff at TheStreet
07:00AM  Actavis' Wide-Moat Transformation Offers Shareholder Rewards at Morningstar
Mar-22-15 01:31PM  Apple Inc. (AAPL) & Alibaba Group Holding Ltd (BABA) Among Five Companies Likes By Five Great Billionaire Investors at Insider Monkey
09:44AM  DURECT Corporation (DRRX): First Eagle Raises Its Stake; See Investors Other Healthcare Picks at Insider Monkey
Mar-21-15 08:02AM  Drug Stocks Are Hot: Meet The 5 Best On The IBD 50 at Investor's Business Daily
Mar-20-15 06:00PM  CEO: My $26 stock going to $200
05:05PM  Why the Feds Patience Has Ironically Created Quite a Stir
07:18AM  Biotech Stock Mailbag: Breaking the Feuerstein-Ratain Rule; Medical Conferences; Celgene at TheStreet
Mar-19-15 04:20PM  AstraZeneca Up on Positive Late-Stage Lung Disease Results - Analyst Blog
01:06PM  Why the Generic Industrys Classification Is Still Evolving
Mar-18-15 07:06PM  Viking Global Increased Its Position in Actavis Plc
05:05PM  Inflows in high-grade bond funds continue but fall Market Realist
01:05PM  Zimmer Holdings and J.M. Smucker are top two issuers
09:42AM  Investors in health-care stocks get rich as M&A booms at MarketWatch
08:13AM  ACTAVIS PLC Files SEC form 8-K, Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition
06:00AM  Jim Cramer's Top Takeaways: Actavis, Apple, General Motors at TheStreet
Mar-17-15 08:12PM  Jim Cramer's 'Mad Money' Recap: This Maddening Market Can't Make Up Its Mind at TheStreet
07:18PM  Cramer Remix: Stocks to buy ahead of Fed meeting at CNBC
06:49PM  Actavis' Depression Drug Gains FDA Approval for New Dose - Analyst Blog
06:25PM  Actavis, Impax Labs Extend Winning Ways at Investor's Business Daily
06:12PM  Cramer: These trends are wreaking havoc right now at CNBC
04:00PM  Stocks close mixed ahead of Fed announcement; Dow off triple digits at CNBC
03:45PM  Allergan sale complete, CEO Pyott steps down at bizjournals.com
02:06PM  Sucampo Pharmaceuticals Revamp Impresses Wall Street at Investor's Business Daily
01:40PM  American Airlines Group (AAL) to Enter Coveted S&P 500 - Analyst Blog
12:45PM  Pharma Stock Outlook: Let's Make a Deal - Zacks Analyst Interviews
12:45PM  Pharma Stock Outlook: Let's Make a Deal - Industry Outlook
11:11AM  Actavis Has More Upside With Allergan Acquisition Says Cramer at TheStreet
10:31AM  Actavis Completes Acquisition of Allergan at The Wall Street Journal
10:19AM  American Airlines Joining The S&P 500, Analysts Bullish On U.S. Skies at Forbes
09:48AM  Actavis says Allergan's Pyott won't join new company's board
09:40AM  American Airlines Replaces Allergan in S&P 500 at 24/7 Wall St.
09:21AM  Actavis Completes Allergan Acquisition at noodls
09:21AM  Cramer's Mad Dash: ACT & MGM
09:17AM  Actavis Completes Allergan Acquisition at noodls
09:17AM  Actavis Announces Michael R. Gallagher and Peter J. McDonnell to Join Board of Directors at noodls
09:13AM  Actavis Receives FDA Approval for VIIBRYD® (vilazodone HCl) 20mg Once Daily as a Therapeutic Dose at noodls
09:13AM  Actavis Completes Allergan Acquisition at noodls
09:10AM  Actavis Announces Michael R. Gallagher and Peter J. McDonnell to Join Board of Directors PR Newswire
08:56AM  Actavis Completes Allergan Acquisition Business Wire
08:54AM  Actavis Completes Allergan Acquisition PR Newswire
08:35AM  6 Stocks Will See Massive Buying and Selling on S&P Quarterly Rebalance at 24/7 Wall St.
08:31AM  Wall Street under pressure as Fed meeting nears at CNBC
08:17AM  EU mergers and takeovers (March 17) Reuters
07:56AM  Early movers: DSW, BABA, EBAY, RTN, AAPL & more at CNBC
Mar-16-15 06:27PM  American Airlines Group Set to Join the S&P 500 PR Newswire
06:23PM  Cramer's March Madness: Top southern stock picks at CNBC
05:50PM  American Airlines to Land in the S&P 500 at Barrons.com
05:46PM  After-hours buzz: Jumei, American Air & more at CNBC
05:00PM  Actavis Receives FDA Approval for Saphris' Label Expansion - Analyst Blog
04:59PM  ACTAVIS PLC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
04:08PM  European Commission Clears Actavis' Pending Acquisition of Allergan at noodls
04:05PM  Actavis Receives FDA Approval for VIIBRYD® (vilazodone HCl) 20mg Once Daily as a Therapeutic Dose PR Newswire
01:40PM  Stocks Hold Near Day's Highs; Medical Issues Gain at Investor's Business Daily
11:13AM  European Commission Clears Actavis' Pending Acquisition of Allergan at noodls
10:58AM  European Commission Clears Actavis Deal to Buy Allergan at The Wall Street Journal
10:57AM  European Commission Clears Actavis' Pending Acquisition of Allergan at noodls
10:52AM  Actavis Receives FDA Approval of SAPHRIS® for Pediatric Patients (age 10-17) for Acute Treatment of Manic or Mixed Episodes of Bipolar I Disorder at noodls
10:26AM  European Commission Clears Actavis Pending Acquisition of Allergan Business Wire
10:22AM  Analyzing Viking Global Investors Positions in 4Q14
10:21AM  European Commission Clears Actavis' Pending Acquisition of Allergan PR Newswire
09:10AM  As Valeant Ups Salix Buyout, Will Endo Come Back? at 24/7 Wall St.
Mar-14-15 08:02AM  3 IBD 50 Stocks That Gained On Big News This Week at Investor's Business Daily
Mar-13-15 10:00PM  Valeant Mulls Higher Salix Bid, But Don't Expect $170 at Investor's Business Daily
06:05PM  Why Did the FOMC Practice Patience in the First Place?
05:50PM  Celgene, Kinder Morgan and Actavis Set to Join the S&P 100; Several Constituent Changes Announced for S&P 500, S&P MidCap 400 and S&P SmallCap 600 PR Newswire
05:06PM  Why investor flows in high-grade bond funds rose Market Realist
04:20PM  Actavis' Generic Pulmicort on Hold until Final Verdict - Analyst Blog
01:39PM  Market safe spots
01:27PM  American Airlines Group (AAL), DISH Network (DISH), Actavis (ACT): Billionaire James Dinans Long-Term Picks at Insider Monkey
01:06PM  Actavis issues $21 billion, the second highest ever
11:26AM  Valeant won't overpay for Salix: Bill Ackman at CNBC
09:30AM  The Zacks Analyst Blog Highlights: NXP Semiconductors, Actavis and Cimpress - Press Releases
08:37AM  Actavis Announces Closing of Public Offering of Senior Notes in Connection with Pending Acquisition of Allergan at noodls
08:33AM  Actavis Confirms Appeals Court Grants Injunction Pending Appeal Related to Generic Pulmicort RESPULES® at noodls
08:00AM  Actavis Receives FDA Approval of SAPHRIS® for Pediatric Patients (age 10-17) for Acute Treatment of Manic or Mixed Episodes of Bipolar I Disorder PR Newswire
Mar-12-15 07:05PM  High-grade corporate bonds hit highest issuance Market Realist
05:00PM  Actavis Confirms Appeals Court Grants Injunction Pending Appeal Related to Generic Pulmicort RESPULES® PR Newswire
04:34PM  Actavis and Allergan Shareholders Approve Proposals Related to Actavis' Planned Acquisition of Allergan at noodls
04:30PM  Actavis and Allergan Shareholders Approve Proposals Related to Actavis' Planned Acquisition of Allergan at noodls
04:30PM  Actavis Announces Closing of Public Offering of Senior Notes in Connection with Pending Acquisition of Allergan PR Newswire
03:46PM  Supernus Gains on Solid Q4 Earnings, Encouraging Guidance - Analyst Blog
Actavis plc develops, manufactures, and sells generic, brand, and biosimilar pharmaceuticals. It offers over-the-counter products. The company also provides biosimilar products in women's health, oncology, and other therapeutic categories. In addition, it offers pharmaceutical products in the areas of urology, gastroenterology, and dermatology therapeutic categories. The company produces medicines in various formulations, including tablets, capsules, injectables, suppositories, sprays, steriles, powders, oral liquids, and semi-solids. It sells its products in Ireland and internationally. Actavis plc was founded in 1983 and is based in Little Island, Ireland. The company has development and manufacturing facilities in Europe, the United States, and Asia.